Heat and immunotherapy join forces against bile duct cancer
NCT ID NCT06440993
First seen Dec 24, 2025 · Last updated Jun 22, 2026 · Updated 38 times
Summary
This phase 2 trial is testing whether combining radiofrequency ablation (a heat treatment) with chemotherapy and the immunotherapy drug durvalumab can improve survival in people with advanced bile duct cancer that cannot be removed by surgery. The study will enroll 42 participants who first receive the heat treatment to clear bile duct blockages, then undergo chemotherapy plus durvalumab. The main goal is to see how many patients are alive after 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTRAHEPATIC CHOLANGIOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Krankenhaus Nordwest
RECRUITINGFrankfurt, 60488, Germany
Contact Email: •••••@•••••
-
Medizinische Hochschule Hannover
RECRUITINGHanover, Germany
Contact
-
UKSH Campus Lübeck
RECRUITINGLübeck, Germany
Contact
-
Uniklinik RWTH Aachen
RECRUITINGAachen, Germany
Contact
-
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz
RECRUITINGMainz, Germany
Contact
-
Universitätsklinik Münster
NOT_YET_RECRUITINGMünster, Germany
Contact
-
Universitätsklinikum Bonn
RECRUITINGBonn, Germany
Contact
-
Universitätsklinikum Düsseldorf
RECRUITINGDüsseldorf, Germany
Contact
-
Universitätsklinikum Köln
RECRUITINGCologne, Germany
Contact
-
Universitätsmedizin Göttingen
RECRUITINGGöttingen, Germany
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
durvalumab (an immunotherapy drug), gemcitabine, cisplatin, and radiofrequency ablation (a heat treatment)
What this could lead to
If successful, this combination could offer a new treatment option that extends survival for people with advanced bile duct cancer.
What could go wrong
This is a small, early-phase trial with only 42 participants, so results may not apply to everyone. The added immunotherapy could cause immune-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.